Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Table of Contents

May 01, 1996; Volume 49,Issue 5
  • You have access
    5-Carboxamido-tryptamine, CP-122,288 and dihydroergotamine but not sumatriptan, CP-93,129, and serotonin-5-O-carboxymethyl-glycyl -tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine1B receptors.
    X J Yu, C Waeber, N Castanon, K Scearce, R Hen, J E Macor, J Chauveau, M A Moskowitz and J Chaveau
    Molecular Pharmacology May 1996, 49 (5) 761-765;
  • You have access
    DNA repair activity in protein extracts of fresh human malignant lymphoid cells.
    J M Barret, P Calsou, G Laurent and B Salles
    Molecular Pharmacology May 1996, 49 (5) 766-771;
  • You have access
    Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors.
    A Skladanowski, S Y Plisov, J Konopa and A K Larsen
    Molecular Pharmacology May 1996, 49 (5) 772-780;
  • You have access
    Transforming growth factor-beta 1 induces transcriptional down-regulation of m2 muscarinic receptor gene expression.
    E B Haddad, J Rousell, J C Mak and P J Barnes
    Molecular Pharmacology May 1996, 49 (5) 781-787;
  • You have access
    Role of c-jun in human myeloid leukemia cell apoptosis induced by pharmacological inhibitors of protein kinase C.
    A J Freemerman, A J Turner, M J Birrer, E Szabo, K Valerie and S Grant
    Molecular Pharmacology May 1996, 49 (5) 788-795;
  • You have access
    Role of nitric oxide in the cytokine-mediated regulation of cytochrome P-450.
    T J Carlson and R E Billings
    Molecular Pharmacology May 1996, 49 (5) 796-801;
  • You have access
    Expression of cytochrome P4502E1 in rat fetal hepatocyte culture.
    D Wu and A I Cederbaum
    Molecular Pharmacology May 1996, 49 (5) 802-807;
  • You have access
    Photoaffinity labeling of the human substance P (neurokinin-1) receptor with [3H2]azido-CP-96,345, a photoreactive derivative of a nonpeptide antagonist.
    D MacDonald, S C Silberman, J A Lowe, S E Drozda, S E Leeman and N D Boyd
    Molecular Pharmacology May 1996, 49 (5) 808-813;
  • You have access
    1-Hydroxyethyl radical formation during NADPH- and NADH-dependent oxidation of ethanol by human liver microsomes.
    D N Rao, M X Yang, J M Lasker and A I Cederbaum
    Molecular Pharmacology May 1996, 49 (5) 814-821;
  • You have access
    Modifications of gamma-aminobutyric acidA receptor subunit expression in rat neocortex during tolerance to diazepam.
    F Impagnatiello, C Pesold, P Longone, H Caruncho, J M Fritschy, E Costa and A Guidotti
    Molecular Pharmacology May 1996, 49 (5) 822-831;
  • You have access
    Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells.
    Y H Ling, A K el-Naggar, W Priebe and R Perez-Soler
    Molecular Pharmacology May 1996, 49 (5) 832-841;
  • You have access
    Selective inhibition of topoisomerase II by ICRF-193 does not support a role for topoisomerase II activity in the fragmentation of chromatin during apoptosis of human leukemia cells.
    H M Beere, C M Chresta and J A Hickman
    Molecular Pharmacology May 1996, 49 (5) 842-851;
  • You have access
    Multiplicity of glutamate receptor subunits in single striatal neurons: an RNA amplification study.
    M B Ghasemzadeh, S Sharma, D J Surmeier, J H Eberwine and M F Chesselet
    Molecular Pharmacology May 1996, 49 (5) 852-859;
  • You have access
    Inhibitory effect of E3330, a novel quinone derivative able to suppress tumor necrosis factor-alpha generation, on activation of nuclear factor-kappa B.
    M Goto, K Yamada, K Katayama and I Tanaka
    Molecular Pharmacology May 1996, 49 (5) 860-873;
  • You have access
    Ahr locus phenotype in congenic mice influences hepatic and pulmonary DNA adduct levels of 2-amino-3-methylimidazo[4,5-f]quinoline in the absence of cytochrome P450 induction.
    P V Nerurkar, H A Schut, L M Anderson, C W Riggs, L W Fornwald, C D Davis, E G Snyderwine, S S Thorgeirsson, W W Weber, J M Rice and G N Levy
    Molecular Pharmacology May 1996, 49 (5) 874-881;
  • You have access
    Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.
    J Balzarini, H Pelemans, M J Pérez-Pérez, A San-Félix, M J Camarasa, E De Clercq and A Karlsson
    Molecular Pharmacology May 1996, 49 (5) 882-890;
  • You have access
    A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2.
    Z H Song and T I Bonner
    Molecular Pharmacology May 1996, 49 (5) 891-896;
  • You have access
    3 alpha-Hydroxy-3 beta-trifluoromethyl-5 alpha-pregnan-20-one (Co 2-1970): a partial agonist at the neuroactive steroid site of the gamma-aminobutyric acidA receptor.
    J E Hawkinson, J A Drewe, C L Kimbrough, J S Chen, D J Hogenkamp, N C Lan, K W Gee, K Z Shen, E R Whittemore and R M Woodward
    Molecular Pharmacology May 1996, 49 (5) 897-906;
  • You have access
    Isoform-specific sensitization of adenylyl cyclase activity by prior activation of inhibitory receptors: role of beta gamma subunits in transducing enhanced activity of the type VI isoform.
    J M Thomas and B B Hoffman
    Molecular Pharmacology May 1996, 49 (5) 907-914;
  • You have access
    Interaction of full and partial agonists of the A1 adenosine receptor with receptor/G protein complexes in rat brain membranes.
    A Lorenzen, L Guerra, H Vogt and U Schwabe
    Molecular Pharmacology May 1996, 49 (5) 915-926;
  • You have access
    Comparison of duration of agonist action at beta 1- and beta 2- adrenoceptors in C6 glioma cells: evidence that the long duration of action of salmeterol is specific to the beta 2-adrenoceptor.
    K E McCrea and S J Hill
    Molecular Pharmacology May 1996, 49 (5) 927-937;
  • You have access
    Ability of nondepolarizing neuromuscular blocking drugs to act as partial agonists at fetal and adult mouse muscle nicotinic receptors.
    G H Fletcher and J H Steinbach
    Molecular Pharmacology May 1996, 49 (5) 938-947;
Back to top
PreviousNext

In this issue

Molecular Pharmacology
Vol. 49, Issue 5
1 May 1996
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
  • The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
  • Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
  • Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
  • The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics